AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3721103 — intervention group
Group type: EXPERIMENTAL
Intervention: Late potentials longer than 75 msec recorded in all patients who had cardiac death.
Number of subjects: 55
Study 3721103 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial dyskinesia present in each patient who developed non-sudden cardiac death.
Number of subjects: 55
Study 11229783 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 11229783 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 11229783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 11229783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31619234 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care in rural health facilities
Number of subjects: 377
Study 30171341 — intervention group
Group type: COMPARATOR
Intervention: Soft laser therapy (15 sessions over 3 weeks)
Number of subjects: 61
Study 30171341 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave therapy (3 treatments over 3 weeks)
Number of subjects: 61
Study 27221864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 34
Study 27221864 — intervention group
Group type: EXPERIMENTAL
Intervention: SULT1A1 copy number (3 copies)
Number of subjects: 34
Study 25444374 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions and in-depth interviews with community members
Number of subjects: 110
Study 22133037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-Augmented Pump Therapy (SAPT)
Number of subjects: 485
Study 22133037 — intervention group
Group type: COMPARATOR
Intervention: Multiple Daily Injection (MDI) therapy with self-monitoring of blood glucose (SMBG)
Number of subjects: 485
Study 20438389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional sodium stibogluconate (SSG)
Number of subjects: 154
Study 20438389 — intervention group
Group type: COMPARATOR
Intervention: Intralesional 7% hypertonic sodium chloride (HS)
Number of subjects: 154
Study 17534784 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 8 weeks
Number of subjects: 18
Study 17534784 — intervention group
Group type: COMPARATOR
Intervention: Sham training (control group)
Number of subjects: 18
Study 16172083 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about betrayal traumas
Number of subjects: 99
Study 16172083 — intervention group
Group type: EXPERIMENTAL
Intervention: Completing an extensive trauma survey
Number of subjects: 99
Study 16172083 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (neutral events)
Number of subjects: 99
Study 16172083 — intervention group
Group type: COMPARATOR
Intervention: Writing about neutral events
Number of subjects: 99
Study 12385596 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg S-PS daily
Number of subjects: 120
Study 12385596 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg S-PS daily
Number of subjects: 120
Study 12385596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10413268 — intervention group
Group type: EXPERIMENTAL
Intervention: Video demonstration of task perceived as very easy (1)
Number of subjects: 0
Study 10413268 — intervention group
Group type: EXPERIMENTAL
Intervention: Video demonstration of task perceived as very difficult (2)
Number of subjects: 0
Study 10413268 — intervention group
Group type: EXPERIMENTAL
Intervention: No video demonstration (3)
Number of subjects: 0
Study 10413268 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllable shooting task at a moving target (1)
Number of subjects: 0
Study 10413268 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrollable shooting task at a moving target (2)
Number of subjects: 0
Study 10413268 — intervention group
Group type: COMPARATOR
Intervention: Control condition with a reading task (3)
Number of subjects: 0
Study 7481155 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0
Study 7481155 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic treatment (various types)
Number of subjects: 0
Study 7481155 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 7481155 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase + Aspirin
Number of subjects: 0
Study 7481155 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase + Aspirin + Heparin
Number of subjects: 0
Study 7481155 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-accelerated t-PA-heparin
Number of subjects: 0
Study 7481155 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated t-PA
Number of subjects: 0
Study 7481155 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 0
Study 2393076 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.125 mg/kg after initial dose of Atracurium 0.5 mg/kg
Number of subjects: 14
Study 2393076 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.125 mg/kg after Alcuronium 0.25 mg/kg
Number of subjects: 14
Study 6778240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate inhalation
Number of subjects: 10
Study 6778240 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate oral
Number of subjects: 10
Study 6778240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31078355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS
Number of subjects: 30
Study 31604589 — intervention group
Group type: EXPERIMENTAL
Intervention: High density of αSMA+ CAFs
Number of subjects: 54
Study 31604589 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased density of CD86+αSMA+ cells
Number of subjects: 54
Study 28836470 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5% cream applied daily for 4 weeks as a primary dressing
Number of subjects: 60
Study 28836470 — intervention group
Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 60
Study 26421700 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation Pillow Group
Number of subjects: 100
Study 26421700 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 100
Study 23340894 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg OD Flex (once-daily insulin degludec with 8-40 hour intervals)
Number of subjects: 687
Study 23340894 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg OD (once-daily insulin degludec at the main evening meal)
Number of subjects: 687
Study 23340894 — intervention group
Group type: COMPARATOR
Intervention: IGlar OD (once-daily insulin glargine at the same time each day)
Number of subjects: 687
Study 23340894 — intervention group
Group type: COMPARATOR
Intervention: IDeg OD Flex vs IGlar OD
Number of subjects: 687
Study 23340894 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg OD Flex vs IDeg OD
Number of subjects: 687
Study 23340894 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 687
Study 21087125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket-sized containers of alcohol-based gel, reminder materials, and education for all healthcare workers (HCWs)
Number of subjects: 333
Study 21087125 — intervention group
Group type: COMPARATOR
Intervention: Basic life support education and workshops for all healthcare workers (HCWs)
Number of subjects: 333
Study 18981188 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Therapy (CIT)
Number of subjects: 32
Study 18981188 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention with hand restraint
Number of subjects: 32
Study 17452906 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (400 mg)
Number of subjects: 20
Study 17452906 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Number of subjects: 20
Study 17452906 — intervention group
Group type: COMPARATOR
Intervention: No itraconazole
Number of subjects: 20
Study 15335180 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of amlodipine
Number of subjects: 30
Study 15335180 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of manidipine
Number of subjects: 30
Study 15335180 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cilnidipine
Number of subjects: 30
Study 11218763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal nicardipine administration (12 ml daily dose, 8 mg of nicardipine for 14 days)
Number of subjects: 5
Study 11218763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal nicardipine administration
Number of subjects: 5
Study 9052891 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg UID)
Number of subjects: 23
Study 9052891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 mg UID)
Number of subjects: 23
Study 9052891 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg BID)
Number of subjects: 23
Study 9052891 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (4 mg UID)
Number of subjects: 23
Study 9052891 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg UID)
Number of subjects: 23
Study 7893227 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR for detection of DNA sequences (65 KDa antigen) of Mycobacterium tuberculosis in CSF samples from test group (10 patients)
Number of subjects: 20
Study 7893227 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20
Study 3239465 — intervention group
Group type: EXPERIMENTAL
Intervention: Project PRIDE participation
Number of subjects: 0
Study 3239465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31387441 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anemia (n=792)
Number of subjects: 5482
Study 27754805 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (7.5 g of 1% testosterone gel daily for 3 years)
Number of subjects: 0
Study 27754805 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gel)
Number of subjects: 0
Study 26328600 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of 100 g/d sugary drinks with 100 g/d milk
Number of subjects: 366
Study 26328600 — intervention group
Group type: COMPARATOR
Intervention: Sugary drink intake
Number of subjects: 366
Study 22959781 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracalcitol (active vitamin D)
Number of subjects: 10
Study 22959781 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet (calcium-sensing receptor agonist)
Number of subjects: 10
Study 21740765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group
Number of subjects: 97
Study 21740765 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 97
Study 21740765 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with microvascular complications
Number of subjects: 97
Study 21740765 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypoglycemic episodes
Number of subjects: 97
Study 21740765 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 97
Study 21740765 — intervention group
Group type: EXPERIMENTAL
Intervention: Long disease course
Number of subjects: 97
Study 21740765 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI patients
Number of subjects: 97
Study 19360440 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic assisted percutaneous nucleotomy (MAPN)
Number of subjects: 100
Study 19360440 — intervention group
Group type: COMPARATOR
Intervention: Standard microsurgical discotomy (MC)
Number of subjects: 100
Study 19360440 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPN
Number of subjects: 100
Study 19360440 — intervention group
Group type: COMPARATOR
Intervention: MC
Number of subjects: 100
Study 16896836 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg meloxicam for 1 month
Number of subjects: 30
Study 16896836 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 1 month
Number of subjects: 30
Study 15488340 — intervention group
Group type: EXPERIMENTAL
Intervention: ASI medical composite score
Number of subjects: 674
Study 15488340 — intervention group
Group type: EXPERIMENTAL
Intervention: ASI psychiatric composite score
Number of subjects: 674
Study 10655195 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 237
Study 10655195 — intervention group
Group type: COMPARATOR
Intervention: Timolol-pilocarpine fixed combination twice daily
Number of subjects: 237
Study 10655195 — intervention group
Group type: COMPARATOR
Intervention: Timolol-pilocarpine
Number of subjects: 237
Study 8862292 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (30 micrograms/kg)
Number of subjects: 16
Study 8862292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1636182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl‐Meyer Assessment at baseline
Number of subjects: 104
Study 1636182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl‐Meyer Assessment at 5 days
Number of subjects: 104
Study 1636182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl‐Meyer Assessment at 30 days
Number of subjects: 104
Study 1636182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample-size calculations based on severity and time since stroke
Number of subjects: 104
Study 6387613 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk protein supplementation
Number of subjects: 51
Study 6387613 — intervention group
Group type: COMPARATOR
Intervention: Human milk supplemented with medium-chain triglyceride (MCT) oil
Number of subjects: 51
Study 31659655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' recommendations accepted by PCPs
Number of subjects: 59
Study 31659655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' recommendations made to PCPs
Number of subjects: 59
Study 31659655 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of pharmacist recommendations
Number of subjects: 59
Study 31659655 — intervention group
Group type: EXPERIMENTAL
Intervention: Accepted recommendations
Number of subjects: 59
Study 30472801 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention (Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve Bb99 and Propionibacterium freudenreichii)
Number of subjects: 1223
Study 30472801 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 1223
Study 30472801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study 28337899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (single dose 30 minutes prior to extraction)
Number of subjects: 20
Study 28337899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug administration before extraction)
Number of subjects: 20
Study 28337899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 26407097 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-approach goals
Number of subjects: 0
Study 26407097 — intervention group
Group type: COMPARATOR
Intervention: Goals with no emphasis on social comparison
Number of subjects: 0
Study 24145423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological intervention targeting the neuroactive ligand-receptor interaction gene set
Number of subjects: 0
Study 24145423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21390581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/(kg·d) for three days)
Number of subjects: 81
Study 21390581 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment and Chinese herbal decoction for purgation)
Number of subjects: 81
Study 19641900 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-psychotic treatment (duration: 3 weeks)
Number of subjects: 20
Study 19641900 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-psychotic treatment (duration: 8 weeks)
Number of subjects: 20
Study 19641900 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-psychotic treatment (duration: 3 and 8 weeks)
Number of subjects: 20
Study 19641900 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 20
Study 17662689 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet (n=116)
Number of subjects: 347
Study 17662689 — intervention group
Group type: COMPARATOR
Intervention: No self-help booklet (n=111)
Number of subjects: 347
Study 17662689 — intervention group
Group type: COMPARATOR
Intervention: Low scorers (n=120)
Number of subjects: 347
Study 15128963 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Number of subjects: 115
Study 15128963 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient services
Number of subjects: 115
Study 12064377 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/Hydrochlorothiazide 20/12.5 mg tablets
Number of subjects: 20
Study 12064377 — intervention group
Group type: COMPARATOR
Intervention: Control formulation of Enalapril/Hydrochlorothiazide 20/12.5 mg tablets
Number of subjects: 20
Study 10362894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine b.i.d.
Number of subjects: 114
Study 10362894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 7887636 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 3
Study 7887636 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMTX
Number of subjects: 3
Study 7887636 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 3
Study 1684979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 3437
Study 6798049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical irrigation with a 10% mannitol solution
Number of subjects: 215
Study 6798049 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparations by digestive tract irrigation with or without intestinal antibiotics
Number of subjects: 215
Study 6798049 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of antibiotics (neomycin, metronidazole by mouth)
Number of subjects: 215
Study 6235682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination preparation of benzoyl peroxide and miconazole cream
Number of subjects: 0
Study 6235682 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide and oral tetracycline
Number of subjects: 0
Study 30354416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (NOAC)
Number of subjects: 0
Study 30354416 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (Control)
Number of subjects: 0
Study 27638053 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU of highly purified menotrophin as single subcutaneous and intramuscular doses
Number of subjects: 121
Study 27638053 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU of highly purified urofollitrophin as single subcutaneous doses
Number of subjects: 121
Study 27638053 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 IU of hp‐FSH as single subcutaneous doses
Number of subjects: 121
Study 27638053 — intervention group
Group type: EXPERIMENTAL
Intervention: daily 225 IU of hp‐FSH as subcutaneous doses for 5 consecutive days
Number of subjects: 121
Study 25055938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day plus tegafur-uracil 400 mg/day (TU) for 2 years
Number of subjects: 169
Study 25055938 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus doxorubicin (40 mg/m2) and cyclophosphamide (500 mg/m2) (ACT) for 2 years
Number of subjects: 169
Study 25055938 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus doxorubicin and cyclophosphamide (ACT) for 2 years
Number of subjects: 169
Study 25055938 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus doxorubicin and cyclophosphamide (ACT)
Number of subjects: 169
Study 25055938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day plus tegafur-uracil 400 mg/day (TU)
Number of subjects: 169
Study 22433757 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen intervention
Number of subjects: 0
Study 20020333 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular multimodal drug injection
Number of subjects: 64
Study 20020333 — intervention group
Group type: COMPARATOR
Intervention: No injection (Control)
Number of subjects: 64
Study 18771405 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol
Number of subjects: 0
Study 18771405 — intervention group
Group type: COMPARATOR
Intervention: 70% (v/v) isopropyl alcohol alone
Number of subjects: 0
Study 15780172 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Androgen Blockade (MAB)
Number of subjects: 0
Study 14624403 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*3 and *4 allele carriers
Number of subjects: 100
Study 14624403 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor metabolizers (PMs)
Number of subjects: 100
Study 14624403 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotyping assay
Number of subjects: 100
Study 10563034 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administered (3 alcoholic drinks each containing approximately 10 g of pure alcohol)
Number of subjects: 40
Study 10563034 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered (equivalent non-alcoholic beverage)
Number of subjects: 40
Study 8951905 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-MIBI from one of two radiopharmacies (exercise scans)
Number of subjects: 303
Study 8951905 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-MIBI from one of two radiopharmacies (rest scans)
Number of subjects: 303
Study 8951905 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-MIBI from one of two radiopharmacies (dipyridamole scans)
Number of subjects: 303
Study 8951905 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise scans
Number of subjects: 303
Study 8951905 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest scans
Number of subjects: 303
Study 8951905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole scans
Number of subjects: 303
Study 8951905 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical reports
Number of subjects: 303
Study 1684155 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 41,656 10 mg
Number of subjects: 12
Study 1684155 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine 0.6 mg s.c.
Number of subjects: 12
Study 6355542 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and sulfinpyrazone
Number of subjects: 0